Clinical Trial Update: Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Niuliva® to prevent hepatitis B virus recurrence in liver transplant recipients. The study is completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Niuliva®

Snippet

Sponsor: Instituto Grifols, S.A. | Conditions: Hepatitis B, Liver Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2016-02-01